drugset / Trial / NCT00699231
Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients
RandomizedParallel-groupDouble-blindPrevention
Summary
This trial is designed to evaluate the immunogenicity, reactogenicity and safety of an MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in haemodialysis patients with or without previous vaccination against hepatitis B
Timeline
- Start
- 1992-02
- Primary completion
- 1992-12
- Completion
- 1992-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine 208129 | Vaccine | — | Intramuscular |